WALDENSTRÖM MACROGLOBULINEMIA (WM)
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA (WM) explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA (WM) trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to deeply shrink rare blood cancer
Disease control Not yet recruitingThis study tests a combination of targeted therapy (zanubrutinib) and reduced-dose chemotherapy for people with untreated Waldenström macroglobulinemia, a rare blood cancer. About 43 participants will receive four cycles of the combo, then eight months of zanubrutinib alone. The …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 06:07 UTC
-
New combo aims to shorten treatment for rare blood cancer
Disease control Not yet recruitingThis early-phase study tests a fixed-duration combination of ibrutinib, bendamustine, and rituximab in 21 adults with Waldenström macroglobulinemia, a rare blood cancer. The goal is to find the safest dose and see if a short treatment course can control the disease without lifelo…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 04:37 UTC